PARP Inhibitors in Advanced Prostate Cancer Care Podcast

CME Available: https://auau.auanet.org/node/37321

Host: Jay D. Raman, MD, FACS

Guests: Maha Hussain, MD and Ganesh Raj, MD, PhD

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Identify approved PARP Inhibitors for prostate cancer and patients who may benefit from PARP Inhibitor‐based therapy.

2. Evaluate available clinical safety and efficacy data for PARP Inhibitors.

3. Describe indications and contraindications for PARP Inhibitors in patients with advanced prostate cancer.

4. Identify how to manage adverse events that patients may experience while taking a PARP Inhibitors.

ACKNOWLEDGEMENTS:

This series is supported by independent educational grants from:

Astellas

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lantheus Medical Imaging

Merck & Co., Inc.

Pfizer, Inc.

Sanofi Genzyme